Squarepoint Ops LLC Savara Inc Transaction History

Squarepoint Ops LLC

  • $62.8 Billion
  • Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Savara Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 44,095 shares of SVRA stock, worth $141,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,095
Previous 112,238 60.71%
Holding current value
$141,104
Previous $452,000 58.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.96 - $5.07 $269,846 - $345,485
-68,143 Reduced 60.71%
44,095 $186,000
Q2 2024

Aug 14, 2024
BUY
$3.66 - $5.34 $410,791 - $599,350
112,238 New
112,238 $452,000
Q1 2023

May 15, 2023
BUY
$1.6 - $2.82 $25,929 - $45,700
16,206 New
16,206 $31,000
Q2 2021

Aug 16, 2021
SELL
$1.51 - $2.29 $65,665 - $99,585
-43,487 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$1.17 - $2.33 $50,879 - $101,324
43,487 New
43,487 $90,000
Q4 2020

Feb 16, 2021
SELL
$1.0 - $1.47 $19,555 - $28,745
-19,555 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$1.09 - $2.21 $58,004 - $117,605
-53,215 Reduced 73.13%
19,555 $21,000
Q2 2020

Aug 14, 2020
BUY
$1.8 - $3.05 $130,986 - $221,948
72,770 New
72,770 $181,000
Q1 2020

May 15, 2020
SELL
$1.91 - $4.08 $84,425 - $180,344
-44,202 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$0.71 - $4.91 $31,383 - $217,031
44,202 New
44,202 $198,000
Q2 2019

Aug 14, 2019
SELL
$2.37 - $11.7 $36,749 - $181,420
-15,506 Closed
0 $0
Q1 2019

May 15, 2019
BUY
$6.71 - $8.6 $104,045 - $133,351
15,506 New
15,506 $114,000

Others Institutions Holding SVRA

# of Institutions
128
Shares Held
158M
Call Options Held
67.6K
Put Options Held
29.4K
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email